# Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock

> **NCT02120404** · PHASE2 · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 45 (estimated)

## Conditions studied

- Septic Shock

## Interventions

- **DRUG:** Esmolol administration

## Key facts

- **NCT ID:** NCT02120404
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120404, "Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02120404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*